Skip to main content
. 2019 May 22;10:584. doi: 10.3389/fphar.2019.00584

Figure 1.

Figure 1

RbCl attenuates osteoclast formation and function without causing cytotoxicity in vitro. (A) Cell viability of osteoclast precursors after RbCl treatment from 24 to 96 h. (B) In vitro osteoclast formation of primary BMMs and RAW264.7 cells after RANKL and RbCl treatment. (C) Quantification of osteoclastogenesis by RbCl. (D) Formation of F-actin ring and bone resorption pits after RANKL and RbCl treatment. (E) Quantification of F-actin ring and bone resorption pits. *p < 0.05 compared with control. Each experiment was repeated biologically in triplicate independently.